Loading patent…
AssigneeThe University of British Columbia
InventorsMartin Gleave, Paul S. Rennie, Hikeaki Miyake, Colleen Nelson, Tobias Zellweger
Estimating the term…
Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
A method for enhancing the chemo- or radiation sensitivity of cancer cells in an individual suffering from a cancer that expresses TRPM-2 in amounts different from normal tissue of the same type, comprising administering to the individual a composition effective to inhibit expression of TRPM-2 by cancer cells.
A method for treating a cancer which expresses TRPM-2 beofre or after treatment with a chemotherapy agent, comprising administering to an individual suffering from the cancer a chemotherapeutic agent which is at least partially effective against the cancer and a composition which reduces the amount of TRPM-2 in cancer cell.
Dependencies are inferred from the claim text.